TB-500 Thymosin Beta-4 Research: Actin Dynamics in Connective Tissue Cell Models
The content, articles and product information provided on this website are strictly educational and informational. They are intended to be used for in vitro research only. “In vitro” is a Latin phrase, “in glass,” that refers to research that is conducted outside of a living organism. Note, these products are not pharmaceuticals or medicines and have not been approved by the FDA for the diagnosis, treatment or prevention of any illnesses or disorders. These products are legally prohibited from human or animal consumption.
TB-500, the synthetic actin-binding fragment of Thymosin Beta-4 corresponding to the LKKTETQ actin-sequestering domain, is studied in vitro for its modulation of G-actin polymerisation equilibrium, cytoskeletal reorganisation, and downstream signalling in fibroblast, tenocyte, and connective tissue cell model preparations. Its defined peptide sequence and characterised actin pharmacology make it a standard research tool for cytoskeletal dynamics studies.
G-Actin Binding Thermodynamics
Isothermal titration calorimetry (ITC) characterises TB-500 binding to monomeric G-actin with Kd values in the 0.5–2 µM range and 1:1 stoichiometry confirmed by binding isotherm analysis. Fluorescence polarisation assays using pyrene-labelled G-actin provide complementary affinity data and enable higher-throughput competition studies. DNase I competition binding assays confirm shared actin monomer surface occupancy between TB-500 and the reference G-actin sequestering protein, establishing the mechanistic basis for actin polymerisation inhibition in downstream cell model studies.
Actin Polymerisation Dynamics in Cell-Free Systems
Pyrene-actin fluorescence polymerisation assays quantify TB-500 effects on actin filament nucleation, elongation rate, and critical concentration shift. Time-course fluorescence curves following actin polymerisation initiation in the presence of defined TB-500 molar ratios characterise concentration-dependent polymerisation inhibition. TIRF microscopy single-filament assays directly visualise barbed-end elongation rates and treadmilling dynamics following TB-500 addition, providing single-molecule mechanistic data on actin pharmacology prior to intact cell model studies.
F-actin/G-actin Ratio Modulation in Fibroblast Models
Human dermal fibroblast (HDF) and NIH 3T3 cell preparations serve as primary connective tissue model systems. Triton X-100 differential extraction followed by western blot quantification of actin in soluble (G-actin) and insoluble (F-actin) fractions establishes the F/G actin ratio shift following TB-500 treatment. Confocal imaging with phalloidin-Alexa Fluor 488 (F-actin) and DNase I-Alexa Fluor 594 (G-actin) dual staining provides spatial resolution of cytoskeletal reorganisation patterns in TB-500-treated fibroblast cell models across concentration ranges.
ILK and Downstream Signalling in Connective Tissue Models
Integrin-linked kinase (ILK) activation has been identified as a downstream signalling consequence of Tβ4/TB-500 pathway engagement in connective tissue cell models. Immunoblot quantification of ILK phosphorylation, downstream Akt Ser473 phosphorylation, and GSK-3β Ser9 phosphorylation characterises the ILK-Akt-GSK3 signalling axis in TB-500-treated fibroblast and tenocyte preparations. Focal adhesion complex assembly — assessed by vinculin, paxillin, and talin immunofluorescence — contextualises ILK activation within cytoskeletal-adhesion signalling in connective tissue cell models.
Tenocyte and ECM Remodelling Applications
Primary human tenocyte and tendon-derived stromal cell preparations provide connective tissue-specific cell model context for TB-500 cytoskeletal research. Sircol collagen assay quantification of secreted collagen, quantitative PCR profiling of COL1A1, COL3A1, MMP-1, MMP-3, and TIMP-1 gene expression, and fibronectin ELISA in conditioned media characterise extracellular matrix remodelling responses associated with TB-500-mediated cytoskeletal pharmacology in tenocyte cell model systems.
3D Connective Tissue Model Applications
Collagen gel contraction assays and 3D fibrin matrix fibroblast culture systems evaluate TB-500 effects in three-dimensional connective tissue model contexts beyond standard monolayer preparations. Gel contraction quantification — measuring projected gel area reduction over 24–72 hour intervals — provides a functional cytoskeletal tension readout linked to TB-500 actin pharmacology. Confocal imaging of F-actin architecture in 3D matrix environments using multi-photon microscopy characterises cytoskeletal organisation in physiologically relevant three-dimensional connective tissue model formats.
Research Summary
TB-500 demonstrates defined thermodynamic G-actin binding, concentration-dependent polymerisation inhibition in cell-free systems, F/G actin ratio modulation in fibroblast cell models, and ILK-Akt pathway activation in connective tissue cell preparations. Its characterised actin pharmacology, tenocyte ECM remodelling endpoint engagement, and 3D model compatibility establish it as a well-defined research peptide for in vitro connective tissue cytoskeletal dynamics studies.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
